Global Biological Drugs Market Size, Share, Trends Analysis to 2020

1. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 Persistence Market Research Global Biological Drugs Market Will Reach US$ 287 Billion in 2020:Persistence Market Research Persistence Market Research 1

2. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 Persistence Market Research Released New Market Report “Global Market Study on Biological Drugs: North America to Witness Highest Growth By 2020”, the global biological drugs market was valued at US$ 161,056.5 Mn in 2014 and is expected to grow at a CAGR of 10.1% from 2014 to 2020, to reach US$ 287,139.7 Mn by 2020. Browse the full report at : http://www.persistencemarketresearch.com/mediarelease/global-biological-drugs- market.asp Biological drugs are typically derived from living cells and are used in the prevention and treatment of various diseases such as cancer, blood disorders, auto-immune diseases, and other medical disorders. Biological drugs have more complex structures compared to that of conventional drugs. Globally, the biological drugs market is witnessing significant growth due to the increasing prevalence of chronic diseases and growing geriatric population. In addition, health and awareness initiatives by various government associations are also supporting the growth of the biological drugs market. However, high costs of biological drugs and patent expiry of blockbuster drugs impede the growth of the biological drugs market. Moreover, risks of adverse effects associated with biologic injectable drugs also inhibit the growth of the market. Request Sample Report: http://www.persistencemarketresearch.com/samples/2883 The global biological drugs market is anticipated to grow from an estimated US$ 161,056.5 Mn in 2014 to US$ 287,139.7 Mn by 2020 at a CAGR 10.1% during the forecast period. North America dominates the global biological drugs market This is due to increasing use of biological drugs in the treatment of diseases such as cancer, diabetes, and other chronic diseases in the region. In addition, several clinics in the region are focusing on biological drugs for the treatment of various diseases. The biological drugs market in Europe is growing due to increasing aging population in the region. For instance, according to a UN report, elderly people accounted for 23.2% of the total population in Germany Persistence Market Research 2

3. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 in 2000, and the number is expected to reach 33.2% by 2025. Aging can lead to certain disorders such as age-related macular degeneration and glaucoma, which require effective biological drugs for their treatment. Low manufacturing costs in Asia are attracting biopharmaceutical companies to invest in the region, supporting the growth of the biological drugs market. Moreover, governments of some Asian countries are also supporting the growth of the biological drugs market by providing funds to life sciences research institutes and biotech companies for the construction of R&D and manufacturing facilities. Novartis AG, Pfizer Inc., GlaxoSmithKline plc., and Merck & Co., Inc. are some of the leading players in the global biological drugs market. Other major players in the market include Abbott Laboratories, Baxter International Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Biogen Idec, and Amgen Inc. The global biological drugs market is segmented as follows: By therapeutic protein • Enbrel • Lantus • Neulasta • Avonex • NovoLog • Rebif • Humalog • Aranesp • Epogen • Levemir • Victoza • Betaseron • Neupogen Persistence Market Research 3

4. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 • Eylea By monoclonal antibody (mAb) • Humira • Remicade • Rituxan • Avastin • Herceptin • Lucentis • By vaccine • Prenvar 13 • Gardasil • Fluzone • Varivax • Cervarix By geography • North America • Europe • Asia Rest of the World (RoW) Market History: Biological drugs are typically derived from living organisms and are mainly used in the prevention and treatment of various chronic diseases such as blood disorders, cancer, auto-immune diseases, and other medical conditions. Persistence Market Research 4

5. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 Globally, the biological drugs market is growing rapidly due to increasing prevalence of chronic diseases and growing geriatric population. In addition, various government associations are promoting the usage of biological drugs for the treatment of diseases. Moreover, advancements in biomedical sciences hold immense potential for the growth of the biological drugs market. The global biological drugs market is anticipated to grow from an estimated US$ 161,056.5 Mn in 2014 to US$ 287,139.7 by 2020, at a CAGR of 10.1% during the forecast period. North America is the largest market for biological drugs. Enbrel is the largest and fastest growing therapeutic protein in the global biological drugs market. In the monoclonal antibody (mAb) segment, Humira is the largest and fastest growing mAb. Prevnar 13 is the largest and fastest growing vaccine in this market. The North America market is anticipated to grow from an estimated US$ 79,225.7 Mn in 2014 to US$ 147,783.8 Mn by 2020 at a CAGR of 10.9% during the forecast period. Table of Content Chapter 1 Preface 11 1.1 Report Description 11 1.2 Report Methodology 12 1.3 Assumptions 12 Persistence Market Research 5

6. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 Chapter 2 Market Synopsis 13 Chapter 3 Porter’s Five Forces Analysis 14 3.1 Bargaining power of suppliers 14 3.2 Bargaining power of buyers 15 3.3 Threat of new entrants 15 3.4 Threat of substitutes 15 3.5 Intensity of rivalry 15 Chapter 4 Industry Overview 17 4.1 Market Definition 17 4.2 Market Drivers 18 4.2.1 Increasing prevalence of chronic diseases 18 4.2.2 Growing geriatric population 19 4.2.3 Rising initiatives by various government associations 20 4.3 Impact Analysis of Market Drivers 21 4.4 Market Restraints 21 4.4.1 High costs of biological drugs 21 4.4.2 Patent expiration of various blockbuster biological drugs 22 4.4.3 Risk of adverse effects associated with biological injectable medicines 22 4.5 Impact analysis of Market Restraints 23 4.6 Opportunities 24 4.6.1 Advancements in biomedical science 24 4.7 Market Trends 24 4.7.1 VEGF therapy is gaining popularity in the biopharmaceutical industry 24 4.7.2 GMOs are gaining importance in the biological drugs market 25 Chapter 5 Global Market Size And Forecast 26 Chapter 6 Market Size and Forecast by Therapeutic Protein 30 6.1 Enbrel 30 6.2 Lantus 33 6.3 Neulasta 35 6.4 Avonex 37 Persistence Market Research 6

7. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 6.5 NovoLog 40 6.6 Rebif 42 6.7 Humalog 44 6.8 Aranesp 46 6.9 Epogen 48 6.10 Levemir 50 6.11 Victoza 52 6.12 Betaseron 54 6.13 Neupogen 56 6.14 Eylea 58 Chapter 7 Market Size and Forecast by mAb 60 7.1 Humira 60 7.2 Remicade 63 7.3 Rituxan 65 7.4 Avastin 67 7.5 Herceptin 70 7.6 Lucentis 72 Chapter 8 Market Size and Forecast by Vaccine 74 8.1 Prenvar 13 74 8.2 Gardasil 77 8.3 Fluzone 79 8.4 Varivax 81 8.5 Cervarix 83 Chapter 9 Market Size and Forecast by Geography 85 9.1 North America 85 9.2 Europe 94 9.3 Asia 103 9.4 Rest of the World (RoW) 112 Chapter 10 Pipeline Biological Drugs 113 10.1 Biological drugs under development for auto-immune diseases 113 10.2 Biological drugs under development for blood diseases 114 Persistence Market Research 7

8. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 10.3 Biological drugs under development for cancer and related conditions 115 10.4 Biological drugs under development for diabetes and cardiovascular diseases 116 Chapter 11 Competitive Scenario 117 11.1 Competitive Benchmarking 117 Chapter 12 Company Profiles 118 12.1 Pfizer Inc. 118 12.1.1 Company Overview 118 12.1.2 Product and Services 119 12.1.3 Financial Performance 119 12.1.4 Recent Developments 120 12.2 Abbott Laboratories 122 12.2.1 Company Overview 122 12.2.2 Product and Services 123 12.2.3 Financial Performance 124 12.2.4 Recent Developments 124 12.3 Novartis AG 125 12.3.1 Company Overview 125 12.3.2 Product and Services 126 12.3.3 Financial Performance 127 12.3.4 Recent Developments 127 12.4 Eli Lilly and Company 129 12.4.1 Company Overview 129 12.4.2 Product and Services 129 12.4.3 Financial Performance 130 12.4.4 Recent Developments 130 12.5 GlaxoSmithKline plc. 131 12.5.1 Company Overview 131 12.5.2 Product and Services 131 12.5.3 Financial Performance 132 12.5.4 Recent Developments 132 12.6 Bristol-Myers Squibb Company 135 12.6.1 Company Overview 135 12.6.2 Product and Services 135 Persistence Market Research 8

9. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 12.6.3 Financial Performance 136 12.6.4 Recent Developments 136 12.7 Merck & Co., Inc. 139 12.7.1 Company Overview 139 12.7.2 Product and Services 139 12.7.3 Financial Performance 140 12.7.4 Recent Developments 140 12.8 Amgen Inc. 142 12.8.1 Company Overview 142 12.8.2 Product and Services 142 12.8.3 Financial Performance 143 12.8.4 Recent Developments 143 12.9 Baxter International Inc. 145 12.9.1 Company Overview 145 12.9.2 Product and Services 145 12.9.3 Financial Performance 146 12.9.4 Recent Developments 146 12.10 Biogen Idec 149 12.10.1 Company Overview 149 12.10.2 Product and Services 149 12.10.3 Financial Performance 150 12.10.4 Recent Developments 150 List of Tables TABLE 1 Market snapshot: Global market for biological drugs (2014 & 2020) 13 TABLE 2 Major biological drugs and their applications 19 TABLE 3 Drivers for global biological drugs market: Impact analysis 21 TABLE 4 Major biological drugs and their adverse effects 23 TABLE 5 Restraints for global biological drugs market: Impact analysis 23 TABLE 6 Global market for biological drugs, by geography, 2009–2013 (US$ Mn) 26 TABLE 7 Global market for biological drugs, by geography, 2014–2020 (US$ Mn) 27 TABLE 8 Global market for biological drugs, by segment, 2009–2013 (US$ Mn) 28 TABLE 9 Global market for biological drugs, by segment, 2014–2020 (US$ Mn) 29 TABLE 10 Global market for Enbrel, by geography, 2009–2013 (US$ Mn) 31 TABLE 11 Global market for Enbrel, by geography, 2014–2020 (US$ Mn) 31 Persistence Market Research 9

10. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 TABLE 12 Global market for Lantus, by geography, 2009–2013 (US$ Mn) 33 TABLE 13 Global market for Lantus, by geography, 2014–2020 (US$ Mn) 34 TABLE 14 Global market for Neulasta, by geography, 2009–2013 (US$ Mn) 35 TABLE 15 Global market for Neulasta, by geography, 2014–2020 (US$ Mn) 36 TABLE 16 Global market for Avonex, by geography, 2009–2013 (US$ Mn) 38 TABLE 17 Global market for Avonex, by geography, 2014–2020 (US$ Mn) 38 TABLE 18 Global market for NovoLog, by geography, 2009–2013 (US$ Mn) 40 TABLE 19 Global market for NovoLog, by geography, 2014–2020 (US$ Mn) 41 TABLE 20 Global market for Rebif, by geography, 2009–2013 (US$ Mn) 42 TABLE 21 Global market for Rebif, by geography, 2014–2020 (US$ Mn) 43 TABLE 22 Global market for Humalog, by geography, 2009–2013 (US$ Mn) 44 TABLE 23 Global market for Humalog, by geography, 2014–2020 (US$ Mn) 45 TABLE 24 Global market for Aranesp, by geography, 2009–2013 (US$ Mn) 46 TABLE 25 Global market for Aranesp, by geography, 2014–2020 (US$ Mn) 47 TABLE 26 Global market for Epogen, by geography, 2009–2013 (US$ Mn) 48 TABLE 27 Global market for Epogen, by geography, 2014–2020 (US$ Mn) 49 TABLE 28 Global market for Levemir, by geography, 2009–2013 (US$ Mn) 50 TABLE 29 Global market for Levemir, by geography, 2014–2020 (US$ Mn) 51 TABLE 30 Global market for Victoza, by geography, 2009–2013 (US$ Mn) 52 TABLE 31 Global market for Victoza, by geography, 2014–2020 (US$ Mn) 53 TABLE 32 Global market for Betaseron, by geography, 2009–2013 (US$ Mn) 54 TABLE 33 Global market for Betaseron, by geography, 2014–2020 (US$ Mn) 55 TABLE 34 Global market for Neupogen, by geography, 2009–2013 (US$ Mn) 56 TABLE 35 Global market for Neupogen, by geography, 2014–2020 (US$ Mn) 57 TABLE 36 Global market for Eylea, by geography, 2009–2013 (US$ Mn) 58 TABLE 37 Global market for Eylea, by geography, 2014–2020 (US$ Mn) 59 TABLE 38 Global market for Humira, by geography, 2009–2013 (US$ Mn) 61 TABLE 39 Global market for Humira, by geography, 2014–2020 (US$ Mn) 61 TABLE 40 Global market for Remicade, by geography, 2009–2013 (US$ Mn) 63 TABLE 41 Global market for Remicade, by geography, 2014–2020 (US$ Mn) 64 TABLE 42 Global market for Rituxan, by geography, 2009–2013 (US$ Mn) 65 TABLE 43 Global market for Rituxan, by geography, 2014–2020 (US$ Mn) 66 TABLE 44 Global market for Avastin, by geography, 2009–2013 (US$ Mn) 68 TABLE 45 Global market for Avastin, by geography, 2014–2020 (US$ Mn) 68 TABLE 46 Global market for Herceptin, by geography, 2009–2013 (US$ Mn) 70 Persistence Market Research 10

11. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 TABLE 47 Global market for Herceptin, by geography, 2014–2020 (US$ Mn) 71 TABLE 48 Global market for Lucentis, by geography, 2009–2013 (US$ Mn) 72 TABLE 49 Global market for Lucentis, by geography, 2014–2020 (US$ Mn) 73 TABLE 50 Global market for Prevnar 13, by geography, 2009–2013 (US$ Mn) 75 TABLE 51 Global market for Prevnar 13, by geography, 2014–2020 (US$ Mn) 75 TABLE 52 Global market for Gardasil, by geography, 2009–2013 (US$ Mn) 77 TABLE 53 Global market for Gardasil, by geography, 2014–2020 (US$ Mn) 78 TABLE 54 Global market for Fluzone, by geography, 2009–2013 (US$ Mn) 79 TABLE 55 Global market for Fluzone, by geography, 2014–2020 (US$ Mn) 80 TABLE 56 Global market for Varivax, by geography, 2009–2013 (US$ Mn) 81 TABLE 57 Global market for Varivax, by geography, 2014–2020 (US$ Mn) 82 TABLE 58 Global market for Cervarix, by geography, 2009–2013 (US$ Mn) 83 TABLE 59 Global market for Cervarix, by geography, 2014–2020 (US$ Mn) 84 TABLE 60 North America market for biological drugs, by country, 2009–2013 (US$ Mn) 86 TABLE 61 North America market for biological drugs, by country, 2014–2020 (US$ Mn) 87 TABLE 62 North America market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 88 TABLE 63 North America market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 89 TABLE 64 North America market for biological drugs, by mAb, 2009–2013 (US$ Mn) 90 TABLE 65 North America market for biological drugs, by mAb, 2014–2020 (US$ Mn) 91 TABLE 66 North America market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 92 TABLE 67 North America market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 93 TABLE 68 Europe market for biological drugs, by country, 2009–2013 (US$ Mn) 95 TABLE 69 Europe market for biological drugs, by country, 2014–2020 (US$ Mn) 95 TABLE 70 Europe market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 97 TABLE 71 Europe market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 98 TABLE 72 Europe market for biological drugs, by mAb, 2009–2013 (US$ Mn) 99 TABLE 73 Europe market for biological drugs, by mAb, 2014–2020 (US$ Mn) 100 TABLE 74 Europe market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 101 TABLE 75 Europe market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 102 TABLE 76 Asia market for biological drugs, by country, 2009–2013 (US$ Mn) 104 TABLE 77 Asia market for biological drugs, by country, 2014–2020 (US$ Mn) 104 Persistence Market Research 11

12. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 TABLE 78 Asia market for biological drugs, by therapeutic protein, 2009–2013 (US$ Mn) 106 TABLE 79 Asia market for biological drugs, by therapeutic protein, 2014–2020 (US$ Mn) 107 TABLE 80 Asia market for biological drugs, by mAb, 2009–2013 (US$ Mn) 108 TABLE 81 Asia market for biological drugs, by mAb, 2014–2020 (US$ Mn) 109 TABLE 82 Asia market for biological drugs, by vaccine, 2009–2013 (US$ Mn) 110 TABLE 83 Asia market for biological drugs, by vaccine, 2014–2020 (US$ Mn) 111 TABLE 84 Some pipeline biological drugs for auto-immune diseases 113 TABLE 85 Some pipeline biological drugs for blood diseases 114 TABLE 86 Some pipeline biological drugs for cancer and related conditions 115 TABLE 87 Some pipeline biological drugs for diabetes and cardiovascular diseases 116 TABLE 88 Pfizer major product segments 119 TABLE 89 Abbott major product categories 123 TABLE 90 Novartis product segments 126 TABLE 91 Lilly product segments 129 TABLE 92 GlaxoSmithKline product segments 131 TABLE 93 Bristol-Myers Squibb key product and brands 135 TABLE 94 Merck key product categories 139 TABLE 95 Amgen product category 142 TABLE 96 Baxter major product categories 145 TABLE 97 Biogen Idec major therapies and their uses 149 List of Figures FIG. 1 Biological drugs market: Porter’s five force analysis 14 FIG. 2 Biological drugs market, by therapeutic proteins, mAbs and vaccine 18 FIG. 3 Geriatric population in major countries, 2000–2050, (% share) 20 FIG. 4 Global market for biological drugs by geography 2013 (% share) 26 FIG. 5 Global market for biological drugs by segment 2013 (% share) 28 FIG. 6 Global market for Enbrel by geography 2013 (% share) 30 FIG. 7 Global market for Lantus by geography 2013 (% share) 33 FIG. 8 Global market for Neulasta by geography 2013 (% share) 35 FIG. 9 Global market for Avonex by geography 2013 (% share) 37 FIG. 10 Global market for NovoLog by geography 2013 (% share) 40 FIG. 11 Global market for Rebif by geography 2013 (% share) 42 FIG. 12 Global market for Humalog by geography 2013 (% share) 44 FIG. 13 Global market for Aranesp by geography 2013 (% share) 46 Persistence Market Research 12

13. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 FIG. 14 Global market for Epogen by geography 2013 (% share) 48 FIG. 15 Global market for Levemir by geography 2013 (% share) 50 FIG. 16 Global market for Victoza by geography 2013 (% share) 52 FIG. 17 Global market for Betaseron by geography 2013 (% share) 54 FIG. 18 Global market for Neupogen by geography 2013 (% share) 56 FIG. 19 Global market for Eylea by geography 2013 (% share) 58 FIG. 20 Global market for Humira by geography 2013 (% share) 60 FIG. 21 Global market for Remicade by geography 2013 (% share) 63 FIG. 22 Global market for Rituxan by geography 2013 (% share) 65 FIG. 23 Global market for Avastin by geography 2013 (% share) 67 FIG. 24 Global market for Herceptin by geography 2013 (% share) 70 FIG. 25 Global market for Lucentis by geography 2013 (% share) 72 FIG. 26 Global market for Prevnar 13 by geography 2013 (% share) 74 FIG. 27 Global market for Gardasil by geography 2013 (% share) 77 FIG. 28 Global market for Fluzone by geography 2013 (% share) 79 FIG. 29 Global market for Varivax by geography 2013 (% share) 81 FIG. 30 Global market for Cervarix by geography 2013 (% share) 83 FIG. 31 North America market for biological drugs, by country, 2013 (% share) 86 FIG. 32 North America market for biological drugs, by therapeutic protein, 2013 (% share) 87 FIG. 33 North America market for biological drugs, by mAb, 2013 (% share) 90 FIG. 34 North America market for biological drugs, by vaccine, 2013 (% share) 92 FIG. 35 Europe market for biological drugs, by country, 2013 (% share) 94 FIG. 36 Europe market for biological drugs, by therapeutic protein, 2013 (% share) 96 FIG. 37 Europe market for biological drugs, by mAb, 2013 (% share) 99 FIG. 38 Europe market for biological drugs, by vaccine, 2013 (% share) 101 FIG. 39 Asia market for biological drugs, by country, 2013 (% share) 103 FIG. 40 Asia market for biological drugs, by therapeutic protein, 2013 (% share) 105 FIG. 41 Asia market for biological drugs, by mAb, 2013 (% share) 108 FIG. 42 Asia market for biological drugs, by vaccine, 2013 (% share) 110 FIG. 43 Competitive landscape of biological drugs market 117 FIG. 44 Pfizer revenue and net income, 2011–2013 (US$ Mn) 119 FIG. 45 Abbott net sales and net earnings, 2011–2013 (US$ Mn) 124 FIG. 46 Novartis net sales and net income, 2011–2013 (US$ Mn) 127 FIG. 47 Lilly revenue and net income, 2011–2013 (US$ Mn) 130 FIG. 48 GlaxoSmithKline turnover and profit, 2011–2013 (US$ Mn) 132 Persistence Market Research 13

14. Global Market Study on Biological Drugs - North America to Witness Highest Growth By 2020 FIG. 49 Bristol-Myers Squibb revenue and net earnings, 2011–2013 (US$ Mn) 136 FIG. 50 Merck sales and net income, 2011–2013 (US$ Mn) 140 FIG. 51 Amgen revenue and net income, 2011–2013 (US$ Mn) 143 FIG. 52 Baxter net sales and net income, 2011–2013 (US$ Mn) 146 FIG. 53 Biogen Idec revenue and net income, 2011–2013 (US$ Mn) 150 About Us: Persistence Market Research is a global market research firm specializing- syndicated research, custom research, and consulting services At Persistence Market Research (PMR), we are in the business of accelerating your business. As a full- service market research firm, we stand committed to bringing more accuracy and speed to your business decisions. From ready-to-purchase market research reports to customized global research solutions, our engagement models are highly flexible without compromising on our deep-seated research values. Briefly stated, our mission is to give you access to forecasts and trends analyses that put you on the path to profitability. PMR’s Services Go Beyond Gleaning Data Most enterprises believe that IT and databases are enough to make an accurate decision. While we do not dispute that, consider this: How long does it take to make an accurate and strategic million-dollar decision? We strive to deliver both even with demanding deadlines. Contact Us: Addie Thomes 305 Broadway 7th Floor, New York City, NY 10007, United States, USA - Canada Toll Free: 800-961-0353 Email: sales@persistencemarketresearch.com Web: http://www.persistencemarketresearch.com Persistence Market Research 14